Convalescent Plasma Therapy for COVID-19: State of the Art.

Autor:	Focosi D; North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy daniele.focosi@gmail.com., Anderson AO; Department of Respiratory Mucosal Immunity, US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA., Tang JW; Respiratory Sciences, University of Leicester, Leicester, United Kingdom., Tuccori M; Division of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.; Unit of Adverse Drug Reaction Monitoring, Pisa University Hospital, Pisa, Italy.
Jazyk:	angličtina
Zdroj:	Clinical microbiology reviews [Clin Microbiol Rev] 2020 Aug 12; Vol. 33 (4). Date of Electronic Publication: 2020 Aug 12 (Print Publication: 2020).
DOI:	10.1128/CMR.00072-20
Abstrakt:	Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored. This review summarizes historical settings of application, with a focus on betacoronaviruses, and surveys current approaches for donor selection and CP collection, pooling technologies, pathogen inactivation systems, and banking of CP. We additionally list the ongoing registered clinical trials for CP throughout the world and discuss the trial results published thus far. (Copyright © 2020 American Society for Microbiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu